Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Meclizine Hydrochloride

FDA-approved product (tablet, chewable, oral), marketed as Antivert, Meclizine Hydrochloride.

Registered studies
11
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Meclizine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic disease
  • Motion sickness
  • Nausea
  • Nausea and vomiting
  • Vertigo
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Piperazine derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

11registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Meclizine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Meclizine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

    NCT07681076 · start 2026-09-03

    Registered record
    Registry ID
    NCT07681076
    Conditions
    Healthy Volunteers
    Interventions
    KarXT; Trimethobenzamide; Ondansetron; Meclizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-09-03
    Completion
    2026-11-30
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionKarXT; Trimethobenzamide; Ondansetron; Meclizine
    PhasePhase 4
    Registry statusRecruiting

  • Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

    NCT05852730 · start 2021-08-10

    Registered record
    Registry ID
    NCT05852730
    Conditions
    Motion Sickness, Space; Motion Simulation; Parabolic Flight
    Interventions
    DPI-386 Nasal Gel; Other (e.g., promethazine, meclizine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-08-10
    Completion
    2026-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMotion Sickness, Space; Motion Simulation; Parabolic Flight
    InterventionDPI-386 Nasal Gel; Other (e.g., promethazine, meclizine)
    PhasePhase 2
    Registry statusRecruiting

  • Meclizine Plasma Levels in Responders and Non-responders

    NCT04482985 · start 2020-09-01

    Registered record
    Registry ID
    NCT04482985
    Conditions
    Seasickness; Meclizine
    Interventions
    Meclizine Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2021-09-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasickness; Meclizine
    InterventionMeclizine Hydrochloride
    PhasePhase 4
    Registry statusUnknown

  • Evaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers

    NCT04564144 · start 2020-06-01

    Registered record
    Registry ID
    NCT04564144
    Conditions
    Emesis
    Interventions
    Meclizine Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2020-06-01
    Completion
    2020-12-01
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmesis
    InterventionMeclizine Hydrochloride
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Meclizine for Hepatocellular Carcinoma

    NCT03253289 · start 2017-10-13

    Registered record
    Registry ID
    NCT03253289
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Meclizine Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-13
    Completion
    2023-03-28
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionMeclizine Oral Tablet
    PhasePhase 1
    Registry statusCompleted

  • Motion Sickness Medications and Vestibular Time Constant

    NCT03270839 · start 2017-06-01

    Registered record
    Registry ID
    NCT03270839
    Conditions
    Drug Reaction
    Interventions
    Bonine 25Mg Chewable Tablet; Kwells; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2020-01-01
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Reaction
    InterventionBonine 25Mg Chewable Tablet; Kwells; Placebo Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

    NCT02112578 · start 2016-11-01

    Registered record
    Registry ID
    NCT02112578
    Conditions
    Vertigo, Peripheral
    Interventions
    Meclizine; Dimenhydrinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-11-01
    Completion
    2017-12-01
    Enrolment
    292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVertigo, Peripheral
    InterventionMeclizine; Dimenhydrinate
    PhasePhase 3
    Registry statusCompleted

  • Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

    NCT02625181 · start 2016-07

    Registered record
    Registry ID
    NCT02625181
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    Automated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery; Anesthesia Information Management System (AIMS); Perioperative Data Warehouse (PDW); General anesthesia; Elective surgery; Propofol; Sevoflurane; Isoflurane; Desflurane; Scopolamine; Droperidol; Haloperidol; Dexamethasone; Promethazine; Meclizine; Aprepitant; Metoclopramide; Fentanyl; Sufentanil; Alfentanil; Remifentanil; Morphine; Meperidine; Hydromorphone; Methadone; Oxycodone; Oxymorphone; Hydrocodone; Ketamine; Ondansetron; Granisetron; Dolasetron mesylate; Palonosetron; Tropisetron; Ramosetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-11-30
    Enrolment
    27,034

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionAutomated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery +34 more
    PhaseNot applicable
    Registry statusCompleted

  • The Effects of Antihistamines on Pre-Pulse Inhibition

    NCT01537471 · start 2012-01

    Registered record
    Registry ID
    NCT01537471
    Conditions
    Healthy
    Interventions
    Placebo; Meclizine; Meclizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-09
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPlacebo; Meclizine; Meclizine
    PhasePhase 1
    Registry statusCompleted

  • Meclizine as a Potential Smoking Cessation Treatment

    NCT01443858 · start 2011-08

    Registered record
    Registry ID
    NCT01443858
    Conditions
    Smoking Cessation
    Interventions
    Meclizine; Nicotine Patch; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-08
    Completion
    2013-07
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoking Cessation
    InterventionMeclizine; Nicotine Patch; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients

    NCT00641797 · start 2006-11

    Registered record
    Registry ID
    NCT00641797
    Conditions
    Benign Paroxysmal Positional Vertigo
    Interventions
    Meclizine; Epley Maneuver; Lorazepam; Diphenhydramine; Ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-11
    Completion
    2013-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Paroxysmal Positional Vertigo
    InterventionMeclizine; Epley Maneuver; Lorazepam; Diphenhydramine +1 more
    PhaseNot applicable
    Registry statusCompleted